生命科学资讯

Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact

Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales

Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials

Sanofi abandons attempt to develop next-gen mRNA seasonal flu vaccine

Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor

AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities

Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B

The new rules of biopharma M&A: 4 trends driving dealmaking this year

Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says

New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill

Eikon sets $274M goal for upcoming stock market debut

Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M

Lilly pens $1.1B pact with German biotech to work on gene editing med for hearing loss

Medtech M&A 'rebounded' in 2025 as softer valuations drove deal competition: report

CalciMedica stock craters as calcium channel inhibitor trial stopped over 'safety concern'

FDA puts clinical hold on Regenxbio gene therapies weeks before approval ruling

'We have an expansive view:' Kardigan CEO knits sharper trials, digital health into cardio strategy

Boehringer channels midstage momentum into pivotal kidney disease trial

With 200 JPM meetings, Novo Nordisk BD head searches for the next Metsera

Rethinking heart attacks as nervous system gone haywire sparks potential new drug targets